Skip to main content
S&P 5007,670.20+1.03%DOW52,607.86+1.04%NASDAQ26,382.63+1.15%BTC$79,041.00+2.66%ETH$2,609.52+7.33%GOLD$4,429.60+0.51%OIL$99.19-3.21%
Smart Investors Daily
OT

OTC · OTLC

Oncotelic Therapeutics, Inc.

Healthcare · Biotechnology

$0.03

Down-$0.00 (-6.25%)

Updated Sep 11, 2026, 2:24 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.83M
P/E ratio
-22.99
Dividend yield
0.00%
52-week range
$0.02 – $0.11
Volume
97.73K
Avg. volume
324.47K

Price performance

OTLC price history

1M range · 5 trading sessions · Daily adjusted prices

OTLC closed at $0.04 after 5 trading sessions, down 12.16% for the selected period.

Last close
$0.04
Period change
-12.16%
Period low
$0.04
Period high
$0.05
Daily close
View OHLC price history
OTLC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 19, 2026$0.038$0.045$0.038$0.041697.73K
Aug 18, 2026$0.0414$0.0459$0.0371$0.0383107.1K
Aug 17, 2026$0.0393$0.0414$0.0388$0.041465.58K
Aug 14, 2026$0.0435$0.048$0.0401$0.0436229.45K
Aug 13, 2026$0.0332$0.05$0.0332$0.0473490.73K

Latest OTLC news

The latest Smart Investors Daily articles mentioning OTLC.

Stock researchCompany · Overview

OTLC research

Overview

Company profile and research snapshot.

Company profile

ONCOTELIC THERAPEUTCS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.08
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 7, 2026

OTCQB Virtual Investor Conference Presentations Now Available for On-Demand Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the August 5th & 6th OTCQB Virtual Investor Conference are available for on-demand viewing. The two-day event featured live presentations from executives representing innovative OTCQB-listed companies across the mining, technology, healthcare, infras

Yahoo · Aug 3, 2026

Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comAGOURA HILLS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Onoctelic Therapeutics Inc. (OTCQB:OTLC), based in Agoura Hills, focused on Oncology Drug Development, today announced that Dr. Vuong Trieu, CEO and Chairman, will present live at the OTCQB Virtual Investor Conference hosted by VirtualInvestorConferences.com, on August 6th, 2026. DATE: August 6th TIME:

Yahoo · Jul 22, 2026

Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)

AGOURA HILLS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the preclinical translational package supporting Sapu003, the Company's intravenous Deciparticle™ formulation of everolimus. The publication provides a complete evaluation of the formulation's absorption, distribution, metabolism, excretion (ADME), pharmacokinetics (PK), tissue distributi

Yahoo · Jun 29, 2026

Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003

Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle™ Technology for Hydrophobic Therapeutics SAN DIEGO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) and Sapu Nano today announced today announced the publication of a peer-reviewed scientific manuscript validating its proprietary Deciparticle™ nanoparticle platform through the successful development of Sapu003, the Co

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By